HIF-2α downregulation in the absence of functional VHL is not sufficient for renal cell differentiation by Hughes, Michael D et al.
BioMed  Central
C
TIONAL INTERNA
CANCER CELL
Page 1 of 11
(page number not for citation purposes)
Cancer Cell International
Open Access Primary research
HIF-2α downregulation in the absence of functional VHL is not 
sufficient for renal cell differentiation
Michael D Hughes†1, Erilda Kapllani†1, Ashlynn E Alexander1, 
Robert D Burk2 and Alan R Schoenfeld*1
Address: 1Department of Biology, Adelphi University, Garden City, NY 11530-0701, USA and 2Departments of Microbiology and Immunology, 
Pediatrics, and Epidemiology and Social Medicine, Marion Bessin Liver Research Center and Albert Einstein Cancer Center, Albert Einstein College 
of Medicine, Bronx, New York, USA
Email: Michael D Hughes - hughes@adelphi.edu; Erilda Kapllani - erk2006@med.cornell.edu; 
Ashlynn E Alexander - ashlynnalexander@adelphi.edu; Robert D Burk - burk@aecom.yu.edu; Alan R Schoenfeld* - schoenfeld@adelphi.edu
* Corresponding author    †Equal contributors
Abstract
Background: Mutational inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene has
been linked to hereditary as well as sporadic clear cell renal carcinomas. The product of the VHL
gene, pVHL, acts to target hypoxia-inducible factor alpha (HIF-α) subunits for ubiquitination and
subsequent degradation. Using an RNA interference approach to lower levels of HIF-2α in two
different renal cell lines that lack functional pVHL, we have tested the contribution of HIF-2α
toward cellular pVHL activities.
Results: Knockdown of HIF-2α resulted in cell cycle arrest of renal cells that were grown on
collagen I, indicating that this pVHL function is dependent on HIF-2α regulation. However, cellular
morphological changes and downregulation of integrins α5 and β1, which were seen upon pVHL
replacement, were not faithfully phenocopied by HIF-2α reduction. Moreover, fibronectin
deposition and expression of renal cell differentiation markers were observed in cells containing
replaced pVHL, but not in HIF-2α knockdown cells, indicating that these pVHL functions may occur
independently of HIF-2α downregulation.
Conclusion: These results indicate that HIF-2α regulation is not sufficient for pVHL-induced renal
cell differentiation. We hypothesize that in addition to HIF-2α dysregulation, abrogation of
additional pVHL functions is required for the initiation of renal carcinogenesis.
Background
von Hippel-Lindau (VHL) disease arises from hetero-
zygous germline mutations in the VHL tumor suppressor
gene, which resides on chromosome 3p25, and is charac-
terized by clear cell renal carcinomas, hemangiomas, phe-
ochromocytomas, as well as other tumor types [1,2]. The
development of tumors in VHL disease results from loss
or inactivation of the remaining wild type allele, leading
to an absence of functional VHL protein [1]. Somatic VHL
mutations are also common in sporadic clear cell renal
carcinoma and hemangioblastomas (reviewed in [2]).
Restoration of VHL function is sufficient to suppress in
vivo tumor formation in VHL-defective renal carcinoma
cells [3,4].
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The VHL gene produces two protein products due to an
internal translation initiation start site at codon 54
[3,5,6]. The larger protein produced from the normal start
site is a 213 amino acid protein approximately 24–30
kDa, (VHLp30), and the shorter produced from the inter-
nal start site is an 18–19 kDa isoform (VHLp19) of 160
amino acids. The shorter form has been shown to contain
full tumor suppressor function [3,5,6]. Both protein prod-
ucts of the VHL gene (collectively called pVHL) contain an
alpha and beta domain [7]. The alpha domain associates
with elongin B, elongin C, Cul2 and Rbx1 and this pVHL
complex acts as a ubiquitin E3 ligase [8-13]. HIF-α, the
alpha subunit of the heterodimeric transcription factor
hypoxia inducible factor (HIF), binds to pVHL's beta
domain and is the best-known substrate of the pVHL E3
ligase complex [14,15].
One of the conditions for pVHL to successfully bind to the
HIF-α subunit is the presence of oxygen [16]. The HIF-α
subunit has an oxygen dependent domain that contains
conserved proline residues that are hydroxylated in the
presence of oxygen [17,18]. This serves as a signal for the
beta domain of pVHL to bind effectively to HIF-α, result-
ing in its polyubiquination and proteosomal degradation.
In hypoxic or anoxic conditions, HIF-α does not get
hydroxylated and is unable to bind pVHL and its levels
remain elevated. Deletion mutations in VHL or point
mutations in the elongin binding domain that result in
loss of functional VHL result in high HIF-α levels [19].
Likewise, point mutations in the beta domain of pVHL
cause a similar effect. VHL disease has been shown to dis-
play a complex genotype-phenotype correlation wherein
specific VHL mutations are associated with a higher risk
for a subset of VHL-associated tumor types [20-22]. The
type 2A disease phenotype is marked by mutations in
pVHL beta domain that hinder its ability to bind HIF-α.
Interestingly, although these mutations lead to higher
HIF-α levels, families with these mutations show a low
incidence of renal cell carcinoma (RCC) [23]. This finding
suggests the possibility of VHL activities other than HIF-α
regulation, the loss of which leads to RCC.
Studies to date have shown that downregulation of HIF-α
is necessary for VHL dependent tumor suppression in
some model systems [24]. However, other model systems
have shown that high levels of HIF-α alone are insufficient
for malignant transformation [25]. Therefore, it is cur-
rently unclear what role HIF-α plays in VHL-associated
tumors, especially with regard to initiation of renal carci-
nomas. In this report, we have examined the role of HIF-
2α regulation in specific cellular phenotypes that have
been previously associated with VHL. Notably, VHL
replacement in VHL-null cells has been shown to regulate
cellular morphology and organization, levels of cell sur-
face integrins, fibronectin matrix assembly, and to direct
growth arrest and cellular differentiation of cells grown on
extracellular matrices [26-28]. Using an RNA interference
approach to lower HIF-2α levels in VHL-null renal cell
lines that express this HIF-α isoform only, we have inves-
tigated whether lower levels of HIF-2α can mimic the
effects of VHL replacement in these cells. Here, we report
that HIF-2α regulation plays a role in certain, but not all
VHL-associated cellular phenotypes. These results suggest
that pVHL has other important biochemical and cellular
functions in addition to the ubiquitination of HIF-α that
may be important for tumor suppression.
Results
786-O and A498 VHL-null renal cell lines both contain
high levels of HIF-2α, but not the other isoforms of HIF-
α [16]. In order to investigate whether downregulation of
HIF-2α is sufficient to mimic VHL replacement in these
cells, we lowered the levels of HIF-2α using two retroviral
vectors that direct the expression of short hairpin RNA
(shRNA) directed against HIF-2α. These constructs are
based on the pSuperRetro shRNA system [29] and have
been previously shown to specifically inhibit HIF-2α in
the 786-O cell line [24]. The empty vector, pSuperRetro,
was used as a control.
We initially infected 786-O cells with single HIF-2α
shRNA retroviruses and selected to obtain a pool of puro-
mycin resistant cells. However, incomplete knockdown of
HIF-2α levels was observed with either of the single
shRNA constructs (Figure 1a, upper panel). To obtain a
more robust downregulation of HIF-2α, 786-O cells were
infected in succession with both HIF-2α shRNA-contain-
ing retroviruses. HIF-2α inhibition was observed in the
doubly infected cells that mimicked the steady state levels
seen in the presence of VHL under normoxia. In parallel,
A498 cells were infected with the two shRNA retroviruses,
resulting in efficient knockdown of HIF-2α (Figure 1b,
upper panel). To ensure that the shRNA was not only
diminishing levels of HIF-2α, but was also causing down-
regulation of HIF target genes, immunoblot analysis was
performed for the GLUT1 protein. As anticipated, down-
regulation of GLUT1 coincided with downregulation of
HIF-2α (Figure 1a, upper middle panel; Figure 1b, upper
middle panel). Thus, in both 786-O and A498 cell lines,
shRNA directed at HIF-2α lowered levels of both HIF-2α
and a representative HIF-responsive target.
Downregulation of HIF-2α in 786-O and A498 cells has
been shown to block tumor formation in nude mice
[24,30]. One mechanism for this tumor suppression
could involve cell cycle arrest. It has been previously
shown that 786-O cells with replaced VHL arrest in the
G0-G1 phase of the cell cycle when cultured on collagen I,
whereas VHL negative cells do not [26]. Cell cycle arrest is
not seen when these cells are cultured by standard meth-Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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ods (i.e., on plastic). To investigate whether HIF-2α plays
a role in cell cycle arrest, 786-O and A498 cell lines were
plated on collagen I and grown to high cell density (2
weeks post-confluency) and analyzed by FACS to assess
cell cycle distributions. Note that under these conditions,
the cell lines utilized formed multilayers of cells. None-
theless, VHL replacement in 786-O cells led to a decreased
percentage of cells in S-phase (Figures 2a and 2d) and an
increased G1 population, as previously reported. Strik-
ingly, knockdown of HIF-2α levels led to an even further
decrease in the fraction of S-phase cells. Similar results
were obtained using the A498 cell lines (Figures 2b and
2d). Of note, both parental and control-infected A498
cells contained a significant percentage of aneuploid cells,
however A498 cells with VHL replaced and those with
shRNA-lowered HIF-2α had no aneuploid cells (Figure
2c). On the whole, removal of HIF-2α appears to be suffi-
cient to mediate cell cycle arrest and suppression of anue-
ploidy in this experimental setting, suggesting that the in
vivo tumor suppression observed may occur at least in part
through this mechanism. However, while these findings
indicate that HIF-2α removal is sufficient to block growth
of VHL-associated renal tumors, it is not clear whether
HIF-2α dysregulation alone can lead to the initiation of
renal carcinomas.
In order to study the role of HIF-2α in processes that may
be more relevant to the earlier stages of renal tumor devel-
opment, we examined additional VHL-mediated activi-
ties. VHL has been shown to play a vital role in
morphological differences of cells grown on collagen I
gels, especially at high cell densities [26]. Under these
conditions, 786-O cells are seen as disorganized, and
branched with a fibroblastic spindly phenotype, whereas
786-O cells in which VHL is replaced form a monolayer of
polygonal cells, with clear cell borders, characteristic of
differentiated epithelia [26]. To determine if these cellular
phenotypic differences are dependent on HIF-2α regula-
tion, the 786-O and A498 cell lines were plated on colla-
gen I and morphological characteristics were observed. As
previously observed, VHL-negative parental and control-
infected 786-O and A498 cells showed a disorganized
fibroblastic, spindly phenotype, whereas cells with VHL
replaced were seen as a monolayer of apparently more dif-
ferentiated cells (Figure 3a and 3b). Also as previously
observed, VHL-negative parental and control-infected
cells displayed a spiral-shaped multicellular organization
(which was more apparent with the 786-O lines) that may
be related to augmented invasiveness and matrix remode-
ling properties and/or disrupted polarity of these cells
[26,31-33]. Importantly, a slightly intermediate pheno-
Successful knockdown of HIF-2α in both 786-O and A498 renal cell lines Figure 1
Successful knockdown of HIF-2α in both 786-O and A498 renal cell lines. (A) Lysates from 786-O cells stably trans-
fected with VHL (VHL +), parental 786-O cells (786-O), and 786-O cells infected with an empty retrovirus (pSuperRetro) or 
with retroviruses encoding single HIF-2α shRNAs (HIF2α shRNA 1; HIF2α shRNA 2) or doubly infected with both shRNAs 
(HIF2α shRNA 1+2) were immunoblotted for HIF-2α (top panel), GLUT1 (upper middle panel) and VHL (lower middle panel). 
Bottom panel is an alpha tubulin immunoblot to demonstrate equal protein loading (25 μg) in each lane. (B) Lysates from A498 
cells stably transfected with VHL (VHL +), parental A498 cells (A498), and A498 cells infected with an empty retrovirus (pSu-
perRetro) or doubly infected with both HIF-2α shRNAs (HIF2α shRNA 1+2) were immunoblotted as in (A).Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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Knockdown of HIF-2α mediates cell cycle arrest on collagen I Figure 2
Knockdown of HIF-2α mediates cell cycle arrest on collagen I. (A) Parental 786-O cells (786-O), 786-O cells stably 
transfected with VHL (VHL +), and 786-O cells infected with an empty retrovirus (pSuperRetro) or doubly infected with both 
HIF-2α shRNAs (HIF2α shRNA 1+2) were grown for 2 weeks after attaining confluence on gels of polymerized collagen I. 
Flow cytometry was performed with a FACScan instrument. Percentages of cells in S phase are shown for each cell line. (B) 
FACS analysis was performed as in (A) using A498 cell lines. (C) Graphical representation of the FACS analysis in (B) with 
arrows highlighting cells with aneuploid DNA content. (D) Complete cell cycle profiles of 786-O and A498 cell lines (diploid 
cells only) from FACS analyses presented in (A), (B), and (C).Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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type that more closely resembled VHL-negative cells was
observed with both the 786-O and A498 cells containing
shRNA-reduced levels of HIF-2α (Figure 3a and 3b).
Cell morphology, motility, and cell spreading have been
shown to be influenced by various integrin proteins that
are expressed at the cell surface. It has been previously
shown that levels of integrins β1, α3, and α5 are downreg-
ulated in 786-O cells with replaced VHL [26]. To deter-
mine the effect of HIF-2α levels on the expression of these
integrins, we prepared lysates from our cell lines, grown
for 7 to 14 days post-confluency on plastic, and subjected
them to immunoblot analysis for α5 and β1 integrins
(Figure 4a and 4b). Both 786-O and A498 cells with
reduced HIF-2α levels demonstrated decreased levels of
these integrins. However, the decreases in α5 integrin and
especially β1 integrin were less striking than that seen with
cells containing intact VHL, indicating that HIF-2α levels
may play a partial role in this cellular phenotype. We also
assessed the levels of α5 and β1 integrins for 786-O cells
that were grown on thin layers of collagen I. Surprisingly,
HIF-2α reduction had no effect on α5 and β1 integrin lev-
els on cells grown on collagen I (Figure 4c), in stark con-
trast to VHL replacement, which efficiently decreased the
levels of these integrins. Thus, proper cell signaling from
extracellular matrices such as collagen I may require pVHL
activities that are independent of or in addition to HIF-2α
regulation.
It has been shown that cells that contain wild-type VHL
properly assemble an extracellular fibronectin matrix
[28,34]. A number of studies have suggested that this cel-
lular VHL activity occurs independently of HIF-α regula-
tion. In order to directly assess whether HIF-2α levels
affect extracellular fibronectin matrix assembly, we quan-
tified the amount of fibronectin deposited by our cell
lines (Figure 5a and 5b). Both 786-O and A498 cells con-
taining ectopically expressed VHL deposited higher con-
centrations of fibronectin in comparison to parental and
control-infected cells. However, 786-O and A498 cells
with shRNA-reduced HIF-2α did not show increased
fibronectin deposition as compared to control or parental
cells and were significantly deficient in comparison to
cells with VHL (P < 0.006 with 786-O VHLp30 cells and P
< 0.009 with A498 VHLp19 cells, Student's paired, two
tailed t-test), indicating that VHL-mediated fibronectin
deposition occurs independently of HIF-2α regulation. It
should be noted that in these assays, 786-O cells express-
ing VHLp19 deposited significantly lower amounts of
fibronectin than those expressing VHLp30 (P < 0.03, Stu-
dent's t-test) and although the levels for either of the VHL-
expressing cells were greater than the parental and control
786-O cells, differences between VHLp19 cells and paren-
tal or control cells did not achieve statistical significance
at the 95% confidence interval (P > 0.05 and P > 0.06,
respectively, Student's t-test). However, fibronectin depo-
sition from A498 cells expressing VHLp19 was signifi-
cantly greater than A498 parental and control cells (P <
0.005 and P < 0.004, respectively), indicating that
VHLp19 does contain this function and that the differ-
ences seen in fibronectin deposition among the VHL-
expressing 786-O cells may be clonal in origin since these
cell lines were derived from single-cell clones [3]. Regard-
less of these minor differences, knockdown of HIF-2α did
not increase fibronectin deposition in either cell line, in
contrast to the effect seen upon VHL replacement.
VHL expression has been previously shown to direct the
expression of cell surface markers of renal cell differentia-
tion in 786-O cells [26]. Prior studies have shown that
Knockdown of HIF-2α has only a slight effect on cell mor- phology Figure 3
Knockdown of HIF-2α has only a slight effect on cell 
morphology. (A) Parental 786-O cells (786-O), 786-O cells 
stably transfected with VHL (VHL +), and 786-O cells 
infected with an empty retrovirus (pSuperRetro) or doubly 
infected with both HIF-2α shRNAs (HIF2α shRNA) were 
grown for 4 days on thin layers of collagen I. Images were 
captured by digital camera mounted on an inverted micro-
scope. (B) Morphological analysis was performed as in (A) 
using A498 cell lines grown for 7 days on thin layers of colla-
gen I.Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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pVHL-mediated differentiation of 786-O renal cells is
dependent on high cell density [26]. Accordingly, 786-O
and A498 cell lines were grown for fourteen days post-
confluency on plastic tissue culture dishes to allow for dif-
ferentiation, and immunoblot analyses were performed
using antibodies to the renal cell surface marker leucine
aminopeptidase, a brush border enzyme found in proxi-
mal tubule epithelium [35]. Expression of leucine ami-
nopeptidase was detected in both the 786-O and A498
cells containing ectopically expressed VHL (Figure 6a and
6b). As expected, expression of this differentiation marker
was not detected in the parental or control cell lines. Nota-
bly, HIF-2α shRNA cell lines also showed no detectable
expression of leucine aminopeptidase. Expression of the
renal marker HNF-1α was also observed in 786-O cells
expressing pVHL, but not in cells with reduced HIF-2α lev-
els (Figure 6c). These results indicate that HIF-2α regula-
tion alone does not cause renal cell differentiation and
that the differentiation process in renal cells is dependent
on other VHL activities.
Discussion
VHL has been linked to a number of phenotypes at the cel-
lular level that may be important for tumor suppression.
In this study, we have analyzed whether certain cellular
VHL functions are dependent on pVHL's ability to regu-
late HIF-2α. We chose cell lines lacking HIF-1α to specifi-
cally examine the isolated role of HIF-2α, and used
retroviral infection to obtain multiclonal pools, limiting
the potential of specific clonal populations. We report
that HIF-2α downregulation was sufficient to cause cell
cycle arrest, whereas VHL-associated cellular morphologi-
cal changes and downregulation of α5 and β1 integrins
were minimally dependent on HIF-2α regulation. Nota-
bly, HIF-2α knockdown was not sufficient to bring about
proper fibronectin matrix assembly and differentiation of
renal cells, both of which are normally mediated by VHL.
Downregulation of HIF-2α levels by shRNA has been
shown to be sufficient to suppress tumor growth of VHL-
defective renal carcinoma cells in nude mice [24,30]. In
the present study, decreased levels of HIF-2α led to cell
cycle arrest of cells grown on collagen I, suggesting a
mechanism for the in vivo growth arrest. Additionally,
knockdown of HIF-2α abrogated aneuploidy in the A498
cell line. These findings reinforce the notion that HIF-2α
is important in the progression of VHL-associated tumors.
This role in renal cells may be specific to HIF-2α (rather
than HIF-1α), since HIF-2α preferentially transactivates
protumorigenic genes, including cyclin D1 and vascular
endothelial growth factor (VEGF) [36]. However, while
many of the clinical manifestations of VHL inactivation,
including tumors with a high degree of vascularization,
might be explained by upregulated hypoxia-inducible
genes, it is doubtful whether HIF-α dysregulation (or HIF-
2α dysregulation) alone can initiate renal tumorigenesis.
In support of this notion, common mutations in the HIF-
α binding domain of pVHL that fall within the type 2A
disease phenotype result in higher levels of HIF-α, yet are
associated with a low incidence of RCC [23]. Additionally,
constitutive expression HIF-2α was seen to be less invasive
in Matrigel than loss of VHL [37]. Overexpression of HIF-
2α was also seen to reduce the growth of rat glioma
tumors and cause apoptosis [38]. Collectively, these find-
Knockdown of HIF-2α has a partial effect on downregulation of α5 and β1 integrins Figure 4
Knockdown of HIF-2α has a partial effect on downregulation of α5 and β1 integrins. (A) Lysates from 786-O cells 
stably transfected with VHL (VHL +), parental 786-O cells (786-O), and 786-O cells infected with an empty retrovirus (pSuper-
Retro) or doubly infected with both HIF-2α shRNAs (HIF2α shRNA 1+2) were immunoblotted for α5 integrin (top panel) and 
β1 integrin (middle panel). Bottom panel is an alpha tubulin immunoblot to demonstrate equal protein loading (25 μg) in each 
lane. (B) Integrin immunoblotting was performed as in (A) using A498 cell lines. (C) Integrin immunoblotting was performed as 
in (A), except cells were grown on thin layers of collagen I.Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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ings suggest that HIF-2α overexpression contributes to
tumorigenesis, but is insufficient for the initiation of renal
carcinomas. Thus, loss of some other VHL-associated
function is required for initiation of renal carcinomas.
Recent studies have focused on a VHL role in earlier stages
of renal tumor development, namely renal cyst formation
[33,39,40]. These studies have suggested that renal cyst
formation may rely more on disruption of VHL functions
such as cell polarity and cilia formation, although the
importance of HIF-α regulation for these phenomena was
not in agreement [33,39]. The role of HIF-2α on other
aspects of cellular morphology is also currently unclear. In
the present studies, HIF-2α knockdown had only a mod-
est effect on cell morphology and on expression of α5 and
β1 integrins. In other studies assessing various parameters
of cell morphology and cell-to-cell interaction, overex-
pression of a constitutively active HIF-2α was seen to have
no effect on adherens junctions (as assayed by β-catenin)
and tight junction organization [32]. On the other hand,
HIF-2α has been seen to regulate the expression of
another adherens junction protein, E-cadherin [39,41]. A
more precise determination of the contribution of HIF-2α
toward adherens junction activities as well the exact rela-
tionship of these markers to VHL-mediated renal tumori-
genesis would clarify these findings.
Fibronectin matrix assembly has been suggested to be a
key VHL function for VHL tumor suppression [37]. In the
present studies, fibronectin deposition was shown to be
unaffected by HIF-2α knockdown. Similarly, cells with
constitutive expression of HIF-2α have been shown to
have intact assembly of fibronectin and collagen IV extra-
cellular matrices [37] and conversely, a pVHL mutant that
retained its ability to ubiquitinate HIF-α failed to promote
fibronectin matrix assembly [34]. These findings all sup-
port the notion that this VHL function is an HIF-α inde-
pendent phenotype. However, it is unlikely that loss of
normal fibronectin assembly is responsible for the initia-
tion of renal tumors, since VHL proteins harboring type
2C disease mutations are defective in fibronectin assem-
bly, yet these mutations are associated with a low risk of
RCC. Also, the differences observed in fibronectin deposi-
tion between 786-O cell lines expressing either of the two
isoforms of VHL in the present studies might indicate a
more subtle role of fibronectin, since these cell lines have
been shown to have equal tumor suppression ability [3].
Another non-HIF-2α associated phenotype observed in
the present studies was VHL-dependent expression of
renal differentiation markers. It is likely that dedifferenti-
ation or failure to differentiate is a very early step in renal
tumorigenesis. Notably, dedifferentiation has been
observed in renal cysts following inactivation of VHL and
changes in a number of renal cell differentiation markers
have been observed in renal cysts [40,42]. Differentiation
may also underlie the formation of primary cilium that is
seen upon VHL replacement in VHL-null cells [33,39].
Knockdown of HIF-2α has no effect on fibronectin deposition Figure 5
Knockdown of HIF-2α has no effect on fibronectin deposition. (A) The amount of fibronectin deposited by 786-O cells 
stably transfected with VHL (VHLp30 and VHLp19), parental 786-O cells (786-O), and 786-O cells infected with an empty ret-
rovirus (pSuperRetro) or doubly infected with both HIF-2α shRNAs (HIF2α shRNA 1+2) was measured by ELISA at 405 nm. 
Error bars represent standard deviation. Differences between VHLp30 cells and all other cell lines were statistically significant 
(P < 0.03). (B) Fibronectin ELISA was performed as in (A) using A498 cells stably transfected with VHL (VHLp19), parental 
A498 cells (A498), and A498 cells infected with an empty retrovirus (pSuperRetro) or doubly infected with both HIF-2α shR-
NAs (HIF2α shRNA 1+2). Differences between VHLp19 cells and all other cell lines were statistically significant (P < 0.009).Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
Page 8 of 11
(page number not for citation purposes)
Interestingly, a type 2A VHL mutant (low risk of RCC) was
seen to support ciliogenesis [33], suggesting that with type
2A VHL mutations, renal cells remain differentiated and
are therefore not capable of initiating a tumor. In contrast
to type 2A VHL disease, specific mutants within the
elongin binding site (type 2B phenotype) correlate with a
high incidence of renal cell carcinoma [23]. Since these
mutations disrupt VHL-mediated ubiquitination as a
whole, it is possible that there is another substrate that the
pVHL complex targets, which is dysregulated in type 2B,
but not type 2A VHL disease. This alternative substrate of
pVHL may be more directly linked to cell differentiation
than HIF-2α and may be more relevant to initiation of
renal carcinomas. However, non-ubiquitination func-
tions of VHL, which have yet to be fully elucidated, may
prove to be more crucial for VHL-mediated differentia-
tion. In either case, it is likely that the loss of VHL-medi-
ated differentiation synergizes with the effects of high
HIF-α levels to lead to the development of renal carcino-
mas.
Conclusion
HIF-2α regulation plays a role in certain, but not all VHL-
associated cellular phenotypes. Notably, HIF-2α regula-
tion is insufficient for pVHL-associated renal cell differen-
tiation. These results suggest that pVHL has other
Knockdown of HIF-2α does not cause renal cell differentiation Figure 6
Knockdown of HIF-2α does not cause renal cell differentiation. (A) Lysates from 786-O cells stably transfected with 
VHL (VHL +), parental 786-O cells (786-O), and 786-O cells infected with an empty retrovirus (pSuperRetro) or doubly 
infected with both HIF-2α shRNAs (HIF-2α shRNA 1+2) were immunoblotted for the renal marker leucine aminopeptidase 
(top panel). Bottom panel is an alpha tubulin immunoblot to demonstrate equal protein loading (25 μg) in each lane. (B) Leu-
cine aminopeptidase immunoblotting was performed as in (A) using A498 cells lines. (C) HNF-1α immunoblotting was per-
formed on 786-O cell lines, as in (A).Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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important biochemical and cellular functions in addition
to the ubiquitination of HIF-α that may be important for
tumor suppression.
Methods
Cell lines and cell culture
All renal cell lines (293T, 786-O and A498) were obtained
from the American Type Culture Collection. All cells were
grown in Dulbecco's modified Eagle's medium containing
10% Serum Supreme (BioWhitaker) and penicillin-strep-
tomycin (100 U/ml and 10 μg/ml, respectively). The 786-
O and A498 renal carcinoma cell lines both contain a sin-
gle VHL allele harboring a frameshift mutation (at codons
104 and 142, respectively) [1,43]. 786-O cells stably trans-
fected with VHLp19 and VHLp30 have been described
previously [3]. A498 cells stably transfected with VHLp19
plasmid [3] were isolated following selection with media
containing 600 μg/ml of G418 [33]. To condition cells at
high density, cells were allowed to grow for 1–2 weeks
post-confluency with media replenishment every 48 h.
For culture on collagen I, cells were either grown on pur-
chased plates coated with a thin layer of collagen I (Becton
Dickinson) or on an approximate 2–3 mm thick layer of
rat collagen I (Becton Dickinson), prepared as previously
described [26]. FACS analysis of cells grown 2 weeks post-
confluency on thick layers of collagen I was performed as
previously described [26]. Analysis of DNA histograms
was performed using ModFitLT 3.1 software (Verity Soft-
ware House). The first major G1 peak with a correspond-
ing G2 peak (containing DNA content double that of G1)
was classified as the diploid cell population, whereas cell
populations displaying alternative G1 peaks with corre-
sponding G2 peaks were classified as anueploid.
Plasmids, Retroviral Production, and Infection
Two retroviral plasmids directing expression of short hair-
pin RNA's (shRNA) containing unique HIF-2α 19mer
sequences [24] were generously provided by Dr. William
Kaelin (Dana Farber Cancer Center). To produce retroviral
supernatants, each retroviral plasmid was transfected into
293T cells plated in duplicate on 35 mm dishes using
Lipofectamine Plus reagent (Invitrogen) as directed by the
manufacturer. Each transfection mix also received the ret-
roviral packing plasmid, pCL-Ampho [44]. Following
transfection, 293T cells from duplicate transfections were
pooled and replated into 100 ml dishes. Medium contain-
ing retroviruses was collected at 72 h post-transfection
and filtered through a 45 μm pore-size filter. To create sta-
ble pools of retrovirally infected cells, 786-O and A498
cells were incubated overnight in a mixture (1:1) of retro-
viral supernatant and fresh medium supplemented with
polybrene (10 μg/ml). Two days later, cells were selected
with puromycin (1 μg/ml) for 10 to 14 days.
Immunoblotting
For all immunoblots, cells were grown to 100% conflu-
ency. Culture plates were rinsed with phosphate buffer
saline (PBS) and cells were lysed using 500 μl of lysis
buffer (50 mM HEPES (pH 7.6), 250 mM NaCl, 0.1%
Nonidet P-40, 5 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM Na2VO3 and 2 μg/ml each of apro-
tinin, bestatin, and leupeptin), incubating at 4°C for 30
minutes. To prepare lysates of cells grown at high density,
the lysis buffer was supplemented with 0.5% Triton X-100
and 0.5% Nonidet P-40 to ensure solubilization of pro-
teins. Lysed cells were scraped with a plastic scraper, resus-
pended by pipetting, collected and then microcentrifuged
for 15 minutes. Supernatant containing clarified protein
lysate was removed and protein levels were determined by
Bradford assay (Bio-Rad). Equal amounts (25 μg) of pro-
tein lysates were added to an appropriate amount of 3.5×
SDS PAGE loading buffer (175 mM Tris (pH 6.8), 0.75
mM DTT, 7% SDS, 35% glycerol, 0.35% bromophenol
blue) and resolved by SDS-polyacrylamide gel electro-
phoresis and subsequently transferred to a polyvinylidene
difluoride (PVDF) membrane overnight. Rabbit polyclo-
nal anti-HIF-2α antibody was from Novus Biological.
Rabbit polyclonal anti-Glut-1 antibody was from Alpha
Diagnostics. Anti-VHL mAb 11E12 has been previously
described [3]. Anti-leucine aminopeptidase mAb was
obtained from Lab Vision/NeoMarkers. Integrin and
HNF-1α mAbs were obtained from BD Transduction Lab-
oratories. Rabbit anti-fibronectin antibody, anti-alpha
tubulin mAb, as well as all secondary rabbit and mouse
antibodies used were from Sigma.
Fibronectin ELISA
Cells (2 × 104) were plated in triplicate in a 96-well tissue
culture plate and grown for six days. Cell removal was per-
formed with Phosphate Buffered Saline (PBS) containing
2 mM EDTA, incubating at 37°C for 5–10 minutes. Com-
plete removal of cells was confirmed by microscopy.
Plates were blocked using TBS-Tween/0.1% BSA (Tris
buffered saline containing 0.5% Tween-20 and 0.1% heat-
inactivated Bovine Serum Albumin) for 45 minutes at
37°C and subsequently incubated with 2 μg/ml of rabbit
anti-fibronectin antibody in TBS-Tween/0.1% BSA for one
hour. Plates were washed three times with TBS-Tween and
then incubated for 45 minutes at 37°C with anti-rabbit
secondary antibody, diluted to a final concentration of 0.1
μg/ml with TBS-Tween/0.1% BSA. Plates were again
washed three times with TBS-Tween and color was devel-
oped with 200 μl of p-nitrophenyl phosphate (Sigma) in
ELISA substrate buffer (1 mg/ml in 50 mM NaCO3, 1 mM
MgCl2, pH 9.8). Reactions were stopped with 50 μl of 3 M
NaOH, and the OD at a wavelength of 405 nm was deter-
mined for each well in a microplate reader (BioRad).Cancer Cell International 2007, 7:13 http://www.cancerci.com/content/7/1/13
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